Total Payments
$8,758
2024 Payments
$464.96
Companies
37
Transactions
224
Medicare Patients
2,911
Medicare Billing
$380,870
Payment Breakdown by Category
Food & Beverage$4,200 (48.0%)
Consulting$3,200 (36.5%)
Travel$805.18 (9.2%)
Education$553.12 (6.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,200 | 209 | 48.0% |
| Consulting Fee | $3,200 | 1 | 36.5% |
| Travel and Lodging | $805.18 | 4 | 9.2% |
| Education | $553.12 | 10 | 6.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $4,354 | 12 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $519.89 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $484.89 | 26 | $0 (2024) |
| Genentech USA, Inc. | $474.49 | 23 | $0 (2020) |
| Astellas Pharma US Inc | $463.16 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $373.04 | 10 | $0 (2024) |
| PFIZER INC. | $346.70 | 30 | $0 (2024) |
| Celgene Corporation | $214.03 | 6 | $0 (2019) |
| ABBVIE INC. | $184.32 | 10 | $0 (2024) |
| Abbott Laboratories | $144.44 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $464.96 | 21 | Novartis Pharmaceuticals Corporation ($98.47) |
| 2023 | $370.27 | 16 | Novartis Pharmaceuticals Corporation ($90.90) |
| 2022 | $241.82 | 11 | Janssen Biotech, Inc. ($91.63) |
| 2021 | $453.82 | 11 | Astellas Pharma US Inc ($344.25) |
| 2020 | $314.46 | 20 | Astellas Pharma US Inc ($55.02) |
| 2019 | $5,864 | 97 | Amgen Inc. ($4,322) |
| 2018 | $724.42 | 39 | Genentech USA, Inc. ($176.89) |
| 2017 | $324.64 | 9 | Celgene Corporation ($128.09) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $26.98 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: Oncology | ||||||
| 10/12/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/30/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Oncology | ||||||
| 05/29/2024 | Boston Scientific Corporation | Wolverine Coronary Cutting Balloon (Device) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Wolverine Coronary Cutting Balloon_IC | ||||||
| 05/28/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Oncology | ||||||
| 05/20/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Immunology | ||||||
| 05/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: Oncology | ||||||
| 04/26/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Oncology | ||||||
| 03/25/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $31.98 | General |
| Category: Oncology | ||||||
| 02/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 10/17/2023 | Boston Scientific Corporation | Wolverine Coronary Cutting Balloon (Device) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: Wolverine Coronary Cutting Balloon_IC | ||||||
| 10/05/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: Oncology | ||||||
| 09/06/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.13 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 737 | 1,059 | $406,699 | $93,177 |
| 2022 | 12 | 699 | 1,025 | $397,532 | $94,476 |
| 2021 | 11 | 749 | 1,082 | $423,876 | $104,619 |
| 2020 | 11 | 726 | 1,070 | $223,821 | $88,599 |
Total Patients
2,911
Total Services
4,236
Medicare Billing
$380,870
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 134 | 302 | $145,796 | $33,536 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 185 | 274 | $90,168 | $20,463 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 72 | 72 | $32,526 | $7,186 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 43 | 43 | $26,419 | $6,250 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 89 | 114 | $25,368 | $5,657 | 22.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 37 | $24,777 | $5,250 | 21.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 51 | 70 | $17,642 | $4,533 | 25.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 42 | $19,399 | $4,468 | 23.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 28 | $10,454 | $2,630 | 25.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 31 | 35 | $5,576 | $1,442 | 25.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 23 | 23 | $6,478 | $1,281 | 19.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 17 | 19 | $2,096 | $480.70 | 22.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 150 | 352 | $168,256 | $40,330 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 132 | 197 | $64,215 | $15,019 | 23.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 51 | 51 | $31,008 | $7,716 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 54 | 54 | $24,192 | $5,278 | 21.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 31 | 32 | $21,312 | $5,239 | 24.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 42 | $19,152 | $4,722 | 24.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 50 | 75 | $17,775 | $4,415 | 24.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 80 | 86 | $18,920 | $4,095 | 21.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 52 | 52 | $14,547 | $3,220 | 22.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 37 | $12,654 | $3,113 | 24.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 23 | 29 | $3,161 | $745.68 | 23.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 18 | $2,340 | $582.70 | 24.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 156 | 368 | $175,455 | $43,437 | 24.8% |
About Dr. David Drew, M.D
Dr. David Drew, M.D is a Hematology & Oncology healthcare provider based in Fort Lauderdale, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1407180615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Drew, M.D has received a total of $8,758 in payments from pharmaceutical and medical device companies, with $464.96 received in 2024. These payments were reported across 224 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($4,200).
As a Medicare-enrolled provider, Drew has provided services to 2,911 Medicare beneficiaries, totaling 4,236 services with total Medicare billing of $380,870. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fort Lauderdale, FL
- Active Since 09/22/2009
- Last Updated 12/05/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1407180615
Products in Payments
- TAGRISSO (Drug) $363.04
- XTANDI (Drug) $264.86
- TECENTRIQ (Biological) $223.79
- Mitra Clip system (Device) $144.44
- IMBRUVICA (Drug) $138.33
- DARZALEX (Biological) $136.96
- Abraxane (Drug) $128.09
- KEYTRUDA (Biological) $127.95
- Avastin (Biological) $117.91
- Erleada (Drug) $111.72
- Lenvima (Drug) $100.04
- ERLEADA (Drug) $95.70
- PROMACTA (Drug) $94.25
- LUTATHERA (Drug) $89.43
- KISQALI (Drug) $85.98
- EMPLICITI (Biological) $77.42
- Venclexta (Drug) $74.11
- VENCLEXTA (Drug) $69.84
- Doptelet (Drug) $69.40
- Revlimid (Drug) $69.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Lauderdale
Dr. Edgardo Santos, Md, MD
Hematology & Oncology — Payments: $2.1M
Hematology & Oncology $2.1M
Dr. Georges Azzi, M.d, M.D
Hematology & Oncology — Payments: $111,744
Hematology & Oncology $111,744
Dr. Evan Wu, Md, MD
Hematology & Oncology — Payments: $53,219
Hematology & Oncology $53,219
Dr. Archana Maini, M.d, M.D
Hematology & Oncology — Payments: $28,974
Hematology & Oncology $28,974
Dr. Tricia Kalwar, Md, MD
Hematology & Oncology — Payments: $2,904
Hematology & Oncology $2,904
Dr. Jeffrey Weisberg, D.o, D.O
Hematology & Oncology — Payments: $15.27
Hematology & Oncology $15.27